by | Oct 22, 2019 | Dhavale, Dhruva, Kotzbauer, Paul, Tu, Zhude "Will", Yue, Xuyi
— Technology Description
A team of researchers at Washington University have developed and optimized highly potent PET imaging probes which are specific for the misfolded protein that is the hallmark of Parkinson’s disease and related disorders. This family of molecules was designed based on s…
by | Oct 22, 2019 | Kotzbauer, Paul, Li, Junfeng, Tu, Zhude "Will", Yue, Xuyi
— Compounds with high affinity for aggregated alpha-synuclein, after radiolabeling with C-11 or F-18, 1- 125, 1-123 and Br-76, could be used as PET tracers to measure the level and distribution of aggregated alpha-synuclein in patients with Parkinson’s disease and related diseases such as DLB…
by | Oct 22, 2019 | Jin, Hongjun, Liu, Hui, Luo, Zonghua, Tu, Zhude "Will"
— Background: Dementia caused by Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases manifests as a progressive decline in memory and other cognitive abilities. Deposits of beta-amyloid plaques and tangles of the tau protein are thought to cause the destruction o…
by | Mar 10, 2018 | Kotzbauer, Paul, Mach, Robert, Tu, Zhude "Will", Yu, Lihai
— A novel series of phenothiazine-derived molecules are useful for detecting Parkinson’s disease using positron emission tomography (PET) imaging. The molecules bind with high affinity to the alpha- synuclein protein, which forms aggregates in the brain and is associated with the neurodegenerati…
by | Mar 10, 2018 | Mach, Robert, Rowland, Douglas, Tu, Zhude "Will", Welch, Michael
— The sigma-2 (σ2) receptor is an important target for the development of molecular probes in oncology because of its 10-fold higher density in proliferating tumor cells than in quiescent tumor cells, and the observation that σ2 receptor agonists are able to kill tumor cells via apoptotic …